This trial is testing a new drug, GEN1046, to see if it is safe and effective in treating patients with non-small cell lung cancer who have progressed after previous treatment.
1 Primary · 10 Secondary · Reporting Duration: Progression-free survival will be assessed from first treatment until 6 months after last subjects first treatment
160 Total Participants · 3 Treatment Groups
Primary Treatment: GEN1046 · No Placebo Group · Phase 2
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: